We are live on ! Find out more
XBI icon

State Street SPDR S&P Biotech ETF

654 hedge funds and large institutions have $12.1B invested in State Street SPDR S&P Biotech ETF in 2020 Q4 according to their latest regulatory filings, with 138 funds opening new positions, 233 increasing their positions, 170 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

318% more first-time investments, than exits

New positions opened: 138 | Existing positions closed: 33

55% more funds holding in top 10

Funds holding in top 10: 1117 (+6)

37% more repeat investments, than reductions

Existing positions increased: 233 | Existing positions reduced: 170

35% more capital invested

Capital invested by funds: $8.96B → $12.1B (+$3.1B)

18% more funds holding

Funds holding: 554654 (+100)

5.19% more ownership

Funds ownership: 171.15%176.34% (+5.2%)

80% less call options, than puts

Call options by funds: $883M | Put options by funds: $4.34B

Holders
654
Holders Change
+100
Holders Change %
+18.05%
% of All Funds
11.57%
Holding in Top 10
17
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+54.55%
% of All Funds
0.3%
New
138
Increased
233
Reduced
170
Closed
33
Calls
$883M
Puts
$4.34B
Net Calls
-$3.46B
Net Calls Change
-$1.53B
Name Holding Trade Value Shares
Change
Change in
Stake
Kayne Anderson Rudnick Investment Management
651
Kayne Anderson Rudnick Investment Management
California
$1K +$1.15K +9 New
WIM
652
Westside Investment Management
California
$896 -$12.8K -100 -2%
Walleye Capital
653
Walleye Capital
New York
$679 +$618K +4,826 New
AIM
654
Axiom Investment Management
New York
$388 -$335K -2,612 -95%
N
655
Natixis
France
-$111M -1,000,000 Closed
ERSOT
656
Employees Retirement System of Texas
Texas
-$17.8M -160,000 Closed
PI
657
PEAK6 Investments
Illinois
-$12.9M -100,347 Closed
GCM
658
Graham Capital Management
Connecticut
-$6.13M -55,000 Closed
MIH
659
Meitav Investment House
Israel
-$4.62M -41,437 Closed
N
660
Nuveen
North Carolina
-$4.35M -39,006 Closed
AGM
661
Alpine Global Management
New York
-$2.94M -26,340 Closed
Ensign Peak Advisors
662
Ensign Peak Advisors
Utah
-$2.75M -24,649 Closed
CL
663
CSS LLC
Illinois
-$3.07M -24,002 Closed
FTUS
664
Flow Traders U.S.
New York
-$1.98M -17,769 Closed
IMC Chicago
665
IMC Chicago
Illinois
-$1.7M -15,296 Closed
IC
666
IEQ Capital
California
-$1.32M -11,893 Closed
BCM
667
Bayesian Capital Management
New York
-$825K -7,400 Closed
AC
668
Aristides Capital
Kentucky
-$535K -4,800 Closed
SWA
669
Stratos Wealth Advisors
Ohio
-$404K -3,622 Closed
PPA
670
Parametric Portfolio Associates
Washington
-$359K -3,224 Closed
WCM
671
Whitener Capital Management
North Carolina
-$273K -2,455 Closed
CS
672
Candriam SCA
Luxembourg
-$252K -2,265 Closed
AI
673
Atom Investors
Texas
-$267K -2,082 Closed
VFPI
674
Vantage Financial Partners (Illinois)
Illinois
-$213K -1,910 Closed
ECM
675
ExodusPoint Capital Management
New York
-$201K -1,800 Closed

XBI Hedge Fund Activity: Q4 2020 in Review

654 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q4 2020, worth a combined $12.1B — up 35% from $8.96B a quarter earlier.

Buyers outnumbered sellers: 138 funds opened new XBI positions and 33 closed out — a net gain of 105 holders — while 233 added to existing stakes and 170 trimmed.

The largest buyer was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, adding an estimated $1.54B. The largest seller was JP Morgan Chase, cutting an estimated $1.23B.

  • 654 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q4 2020, up from 554 in Q3 2020.
  • Funds reported $12.1B of State Street SPDR S&P Biotech ETF stock for Q4 2020, up 35% quarter-over-quarter.
  • 138 funds opened new State Street SPDR S&P Biotech ETF positions in Q4 2020 and 33 closed out, a net change of +105 holders.
  • The largest State Street SPDR S&P Biotech ETF buyer in Q4 2020 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $1.54B added.
  • The largest State Street SPDR S&P Biotech ETF seller in Q4 2020 was JP Morgan Chase, an estimated $1.23B sold.

Based on aggregated 13F filings for Q4 2020.